0
September 1997, Vol 115, No. 9 >
ARTICLE | September 1997

Latanoprost and Hyperpigmentation of Eyelashes FREE

Martin Wand, MD
Arch Ophthalmol. 1997;115(9):1206-1208. doi:10.1001/archopht.1997.01100160376025
Text Size: A A A
Published online
Article
References
Comments

Latanoprost (Xalatan, Pharmacia Upjohn Co, Kalamazoo, Mich) is the first new class of antiglaucoma medication introduced in 20 years. Initial reports about its ocular hypotensive effects seem to be promising, but it has an intriguing side effect of increasing iris pigmentation. On a theoretical basis, hyperpigmentation of periocular structures also

REFERENCES

1 +
Alm A, Stjernschnatz J, Scandanavian Latanoprost Study Group.  Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning . Ophthalmology . 1995;;102:1743-1752.
2 +
Watson P, Stjernschantz J,  Latanoprost Study Group. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension . Ophthalmology . 1996;;103:126-137.
3 +
Camras CB, the United States Latanoprost Study Group.  Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma . Ophthalmology . 1996;;103:138-147.
4 +
Camras CB, Alm A, Watson P, et al.  Latanoprost, a prostaglandin analog, for glaucoma therapy: efficacy and safety after 1 year of treatment in 198 patients . Ophthalmology . 1996;;103:1916-1924.
5 +
Kang S, Sober AJ.  Disturbances of melanin pigmentation . In: Moschella SL, Marley MJ, eds. Dermatology . 3rd ed. Philadelphia, Pa: WB Saunders Co; 1992;:1442-1474.
6 +
Nordlund JJ.  Introduction to the biology at the pigment system . In: Moschella SL, Marley MJ, eds. Dermatology . 3rd ed. Philadelphia, Pa: WB Saunders Co; 1992;:1421-1441.
7 +
Abdel-Malek ZA, Swope VB, Amornsiripanitch N, et al.  In vitro modulation of proliferation and melanization of S91 melanoma cells by prostaglandins . Cancer Res . 1987;;47:3141-3146.
8 +
Nordlund JJ, Collins CE, Rheins LA.  Prostaglandins E2 and D2 but not MSH stimulate the proliferation of pigment cells in the pinnal epidermis of DBA/2 mouse . J Invest Dermatol . 1986;;86:433-437.
9 +
Hadley ME, Levine N.  Hormonal control of melanogenesis . In: Levine N, ed. Pigmentation and Pigmentary Disorders . Boca Raton, Fla: CRC Press Inc; 1993;:95-114.
10 +
Arnoult L, Bowman ZL, Kimbrough RL, et al.  Periocular cutaneous pigmentary changes associated with topical betaxolol . J Glaucoma . 1995;;4:263-267.
11 +
Jakubovic HR, Ackerman AB.  Structure and function of skin: development, morphology and physiology . In: Moschella SL, Marley MJ, eds. Dermatology . 3rd ed. Philadelphia, Pa: WB Saunders Co; 1992;:24-29.
12 +
Prota G. Melanins and Melanogenesis . Orlando, Fla: Academic Press Inc; 1952;.
13 +
Westerhof W, Nanninga PB.  Graying of hair in humans: morphological biological data . In: Bergdorf WMC, Katz SI, eds. Dermatology: Progress and Perspectives . Pearl River, NY: Parthenon Publishing Group Inc; 1993;:508-512.

First Page Preview

First page PDF preview

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

1 +
Alm A, Stjernschnatz J, Scandanavian Latanoprost Study Group.  Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning . Ophthalmology . 1995;;102:1743-1752.
2 +
Watson P, Stjernschantz J,  Latanoprost Study Group. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension . Ophthalmology . 1996;;103:126-137.
3 +
Camras CB, the United States Latanoprost Study Group.  Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma . Ophthalmology . 1996;;103:138-147.
4 +
Camras CB, Alm A, Watson P, et al.  Latanoprost, a prostaglandin analog, for glaucoma therapy: efficacy and safety after 1 year of treatment in 198 patients . Ophthalmology . 1996;;103:1916-1924.
5 +
Kang S, Sober AJ.  Disturbances of melanin pigmentation . In: Moschella SL, Marley MJ, eds. Dermatology . 3rd ed. Philadelphia, Pa: WB Saunders Co; 1992;:1442-1474.
6 +
Nordlund JJ.  Introduction to the biology at the pigment system . In: Moschella SL, Marley MJ, eds. Dermatology . 3rd ed. Philadelphia, Pa: WB Saunders Co; 1992;:1421-1441.
7 +
Abdel-Malek ZA, Swope VB, Amornsiripanitch N, et al.  In vitro modulation of proliferation and melanization of S91 melanoma cells by prostaglandins . Cancer Res . 1987;;47:3141-3146.
8 +
Nordlund JJ, Collins CE, Rheins LA.  Prostaglandins E2 and D2 but not MSH stimulate the proliferation of pigment cells in the pinnal epidermis of DBA/2 mouse . J Invest Dermatol . 1986;;86:433-437.
9 +
Hadley ME, Levine N.  Hormonal control of melanogenesis . In: Levine N, ed. Pigmentation and Pigmentary Disorders . Boca Raton, Fla: CRC Press Inc; 1993;:95-114.
10 +
Arnoult L, Bowman ZL, Kimbrough RL, et al.  Periocular cutaneous pigmentary changes associated with topical betaxolol . J Glaucoma . 1995;;4:263-267.
11 +
Jakubovic HR, Ackerman AB.  Structure and function of skin: development, morphology and physiology . In: Moschella SL, Marley MJ, eds. Dermatology . 3rd ed. Philadelphia, Pa: WB Saunders Co; 1992;:24-29.
12 +
Prota G. Melanins and Melanogenesis . Orlando, Fla: Academic Press Inc; 1952;.
13 +
Westerhof W, Nanninga PB.  Graying of hair in humans: morphological biological data . In: Bergdorf WMC, Katz SI, eds. Dermatology: Progress and Perspectives . Pearl River, NY: Parthenon Publishing Group Inc; 1993;:508-512.

Correspondence

Submit a Letter
CME Course for:


You need to register in order to view this quiz.


To understand the clinical management of acute heart failure syndromes.
Accreditation Information The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
To view and print your certificate and access a summary of your CME courses go to My CME.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Compression-Only CPR: Pushing the Science Forward
Cone
AAM 2010;304:1493-1495.
All you need to read in the other general journals
BMJ 2010;341:c5893-c1494.
Submit a Comment

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

© 2012 American Medical Association. All Rights Reserved.
Powered bySilverchair Information Systems